142 related articles for article (PubMed ID: 30724288)
1. A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles.
Lu M; Henry CE; Lai H; Khine YY; Ford CE; Stenzel MH
Biomater Sci; 2019 Mar; 7(4):1652-1660. PubMed ID: 30724288
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Antimetastatic Activity of the Ruthenium Anticancer Drug RAPTA-C Delivered in Fructose-Coated Micelles.
Lu M; Chen F; Noy JM; Lu H; Stenzel MH
Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28234423
[TBL] [Abstract][Full Text] [Related]
3. Anti-metastatic effects of RAPTA-C conjugated polymeric micelles on two-dimensional (2D) breast tumor cells and three-dimensional (3D) multicellular tumor spheroids.
Lu H; Blunden BM; Scarano W; Lu M; Stenzel MH
Acta Biomater; 2016 Mar; 32():68-76. PubMed ID: 26689468
[TBL] [Abstract][Full Text] [Related]
4. Enhanced delivery of the RAPTA-C macromolecular chemotherapeutic by conjugation to degradable polymeric micelles.
Blunden BM; Lu H; Stenzel MH
Biomacromolecules; 2013 Dec; 14(12):4177-88. PubMed ID: 24266669
[TBL] [Abstract][Full Text] [Related]
5. Combination of ruthenium(II)-arene complex [Ru(η
Berndsen RH; Weiss A; Abdul UK; Wong TJ; Meraldi P; Griffioen AW; Dyson PJ; Nowak-Sliwinska P
Sci Rep; 2017 Feb; 7():43005. PubMed ID: 28223694
[TBL] [Abstract][Full Text] [Related]
6. Cellular responses of BRCA1-defective HCC1937 breast cancer cells induced by the antimetastasis ruthenium(II) arene compound RAPTA-T.
Nhukeaw T; Hongthong K; Dyson PJ; Ratanaphan A
Apoptosis; 2019 Aug; 24(7-8):612-622. PubMed ID: 31016421
[TBL] [Abstract][Full Text] [Related]
7. Precious metal carborane polymer nanoparticles: characterisation of micellar formulations and anticancer activity.
Barry NP; Pitto-Barry A; Romero-Canelón I; Tran J; Soldevila-Barreda JJ; Hands-Portman I; Smith CJ; Kirby N; Dove AP; O'Reilly RK; Sadler PJ
Faraday Discuss; 2014; 175():229-40. PubMed ID: 25270092
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
[TBL] [Abstract][Full Text] [Related]
9. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
10. Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1.
Ratanaphan A; Nhukeaw T; Hongthong K; Dyson PJ
Anticancer Agents Med Chem; 2017; 17(2):212-220. PubMed ID: 27039925
[TBL] [Abstract][Full Text] [Related]
11. An organotypic model of high-grade serous ovarian cancer to test the anti-metastatic potential of ROR2 targeted Polyion complex nanoparticles.
Joshi N; Liu D; Dickson KA; Marsh DJ; Ford CE; Stenzel MH
J Mater Chem B; 2021 Nov; 9(44):9123-9135. PubMed ID: 34676865
[TBL] [Abstract][Full Text] [Related]
12. Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands.
Kilpin KJ; Cammack SM; Clavel CM; Dyson PJ
Dalton Trans; 2013 Feb; 42(6):2008-14. PubMed ID: 23187957
[TBL] [Abstract][Full Text] [Related]
13. RAPTA-Decorated Polyacrylamide Nanoparticles: Exploring their Synthesis, Physical Properties and Effect on Cell Viability.
Sandland J; Savoie H; Boyle RW; Murray BS
Chembiochem; 2021 Mar; 22(5):931-936. PubMed ID: 33095468
[TBL] [Abstract][Full Text] [Related]
14. Antineoplastic nano-lipobubbles for passively targeted ovarian cancer therapy.
Frank D; Indermun S; Govender M; Kumar P; Choonara YE; du Toit LC; Pillay V
Colloids Surf B Biointerfaces; 2019 May; 177():160-168. PubMed ID: 30731392
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
[TBL] [Abstract][Full Text] [Related]
16. Organometallic ruthenium(II) arene compounds with antiangiogenic activity.
Nowak-Sliwinska P; van Beijnum JR; Casini A; Nazarov AA; Wagnieres G; van den Bergh H; Dyson PJ; Griffioen AW
J Med Chem; 2011 Jun; 54(11):3895-902. PubMed ID: 21534534
[TBL] [Abstract][Full Text] [Related]
17. Polymeric Micelle-Mediated Delivery of DNA-Targeting Organometallic Complexes for Resistant Ovarian Cancer Treatment.
Duan X; Liu D; Chan C; Lin W
Small; 2015 Aug; 11(32):3962-72. PubMed ID: 25963931
[TBL] [Abstract][Full Text] [Related]
18. Dual drug delivery system of RAPTA-C and paclitaxel based on fructose coated nanoparticles for metastatic cancer treatment.
Lu M; Wang S; Khine YY; Hong Y; Zheng J; Lu H; Stenzel MH
Biochem Biophys Res Commun; 2023 Jan; 640():134-141. PubMed ID: 36508926
[TBL] [Abstract][Full Text] [Related]
19. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum.
Kenny HA; Krausz T; Yamada SD; Lengyel E
Int J Cancer; 2007 Oct; 121(7):1463-72. PubMed ID: 17546601
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic and Anticancer Properties of Bifunctional Ruthenium(II)-p-Cymene Complexes: Influence of Pendant Perfluorous Chains.
Nowak-Sliwinska P; Clavel CM; Păunescu E; te Winkel MT; Griffioen AW; Dyson PJ
Mol Pharm; 2015 Aug; 12(8):3089-96. PubMed ID: 26158308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
